ClinicalTrials.gg
CompletedNCT04889105Smart MOVEUpdated Nov 10, 2026

Exercise Therapy for PAD Using Mobile Health

An interventional study of Smart MOVE! and General walking advice in Peripheral Artery Disease, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now CompletedNow Active, not recruiting+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Peripheral Arterial Disease by VA Office of Research and Development — 5 open to participants now, 6 under way, 1 of them phase 3. Peripheral Arterial Disease · VA Office of Research and Development.

Enrollment
7th of 15
63 · median 56
Started
2021
with 2 others
No phase
12 of 16
3 open now
Registered
8th of 16
by date

Among the 16 studies in Peripheral Arterial Disease by VA Office of Research and Development, this one is the 7th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2021, is one of 12 with no phase, and was the 8th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

5 of the 16 studies in Peripheral Arterial Disease by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Peripheral Arterial Disease by VA Office of Research and Development, or all of them as a file.
02

Study summary

Peripheral artery disease (PAD) is a highly prevalent condition affecting up to 10% of Veterans that leads to loss of walking ability and increased risk of amputation. Veterans have limited access to supervised exercise therapy, a facility-based program proven to improve walking ability in PAD, which is poorly attended due to the inconvenience and cost of attending a 12-week program with multiple weekly sessions. This CDA-2 application will investigate the feasibility of home-based exercise therapy (HBET) delivered using mobile health (mHealth) technologies in Veterans with symptomatic PAD. The investigators will partner with the MOVE! program to deliver HBET through group behavioral coaching and a novel wearable activity monitor in a newly proposed program called Smart MOVE!. There is a clear need to provide effective and convenient alternatives to supervised exercise for Veterans with PAD. This study will provide evidence to proceed with Smart MOVE!, a much-needed patient-centered rehabilitation program for Veterans with PAD.

Read the detailed description

An estimated 8.5 million Americans (or 7% of US adults) and nearly 10% of Veterans are estimated to have peripheral arterial disease (PAD). Significantly debilitating and negatively impacting quality of life, the primary symptom of PAD is claudication (reproducible leg pain with ambulation) that leads to impaired mobility, loss of functional independence, and a heightened risk for amputation. Veterans are at an increased risk of developing symptomatic PAD due to their disproportionately high rates of PAD risk factors such as diabetes, smoking, and hypertension, the most prominent PAD risk factors.

Supervised exercise therapy is proven to decrease claudication and enhance mobility in PAD; however, fewer than 25% of eligible patients enroll. Participation in this facility-based program requires travel to a rehabilitation center 3 times per week for 12-weeks, which can be burdensome and costly for Veterans, many of whom live in rural areas and on fixed incomes. There is, therefore, a need to develop a convenient and effective alternative exercise rehabilitation program for Veterans with PAD, particularly in light of safety considerations now associated with this population's travel to group facilities in the current COVID pandemic.

A promising approach to increase access to exercise rehabilitation for PAD is remote, home-based exercise therapy (HBET). HBET programs combine self-led walking exercises with health coaching and exercise tracking with a wearable activity monitor. Adapting HBET to PAD is difficult, however, due to the added complexity of an exercise prescription that requires the patient to walk until they experience near-maximal leg pain. Even with active coaching, successfully implementing HBET for PAD with long-term adherence has been difficult in the past. The goal is of this study is to leverage newer mobile health (mHealth) tools to adapt HBET for PAD.

This technology-enhanced approach for HBET will be conducted by partnering with a successful VA lifestyle program, MOVE!, which has demonstrated success in achieving sustained weight loss and reduced diabetes onset through lifestyle modification. As increased physical activity is a core element of MOVE!, participation may help increase adherence with HBET for PAD. This newly proposed program, Smart MOVE!, will be a multi-component program featuring a tailored version of MOVE! and a novel mHealth device to improve convenience, access, and adherence to HBET for PAD.

03

Conditions studied

  • Peripheral Artery Disease

Keywords

  • Mobile health
  • Telemedicine
  • Peripheral artery disease
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Eligible Veteran status
  • Clinically stable intermittent claudication (2 months of Rutherford Class II symptoms, no evidence of chronic limb-threatening ischemia)
  • Established peripheral artery disease (PAD) diagnosis (abnormal ankle-brachial index or evidence of PAD on prior certified vascular laboratory or radiology imaging)
  • Access to safe location to perform walking exercises

Exclusion criteria

Exclusion Criteria:

  • Above or below knee amputation

    • critical limb ischemia (rest pain or tissue loss including ulceration or gangrene)
    • inability to walk without a walker
    • wheelchair confinement
    • non-English speaking
    • significant visual impairment that interferes with walking activity
    • hearing impairment that interferes with full study participation
    • unable or unwilling to return to the medical center at the expected visit frequency or unable or unwilling to use the technology required for the intervention
  • Individuals whose walking is limited by a condition other than peripheral artery disease (PAD)
  • Any active cardiac condition including unstable angina

    • unstable atrial or ventricular arrhythmias
    • high-grade heart block without a pacemaker
    • active myopericarditis
    • recent venous thromboembolism
    • or recent abnormal baseline stress test suggesting ischemia
    • other high-risk findings (e.g., drop of systolic blood > 20 millimetres of mercury (mmHg) with exercise)
  • Presence of Class III heart failure or CCS III angina
  • Major surgery including lower extremity revascularization or orthopedic surgery during the preceding three months or anticipated in the next nine months
  • Major medical illness including lung disease requiring continuous oxygen (patients wearing nighttime oxygen only may still qualify)

    • neurodegenerative disorders such as Parkinson's Disease that impair walking ability
    • cancer requiring treatment in the past 2 years (with exception for non-melanoma skin cancer or if they received treatment for early-stage cancer with an excellent overall prognosis)
  • Heart attack, stroke, or coronary artery bypass surgery in the preceding 3 months
  • Mental health illness that may interfere with the ability to consent and/or participate in the study, including mini-mental status examination score \<24

    • dementia
    • active psychiatric disorder such as schizophrenia or bipolar disorder
    • history of suicidal or homicidal ideation in the preceding six months
    • history of suicidal attempts in the preceding 12 months
    • history of active substance use in the preceding six months that would interfere with study participation (as determined by their primary care or mental health provider)
  • Subjects endorsing SI or HI may be eligible for continued participation with monitoring if approved by their primary mental health provider
  • Currently walking regularly for exercise at a level comparable to the amount of exercise prescribed in the intervention
  • Currently enrolled in another clinical trial or structured exercise program (i.e., cardiac rehabilitation)
  • Deemed to be poorly suited for the study or the study intervention at the discretion of the principal investigator (PI) or study staff
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
63 participants (actual)

Study arms

  • Other
    Performance evaluation

    Preliminary performance evaluation to refine the Smart MOVE! intervention.

    Behavioral: Performance evaluation

  • Active comparator
    Smart MOVE!

    Participants will be enrolled in the multi-component Smart MOVE! intervention for 12 weeks.

    Behavioral: Smart MOVE!

  • Placebo comparator
    Usual care

    Participants will receive general walking advice for 12 weeks.

    Behavioral: General walking advice

Interventions

  • BehavioralSmart MOVE!

    Multi-component behavioral intervention of peripheral artery disease (PAD) consisting of: 1. guideline-directed home-based exercise therapy (HBET) prescription 2. active behavioral coaching (via MOVE! program or other) 3. mobile health monitoring

  • BehavioralGeneral walking advice

    Basic guidance on performing walking exercises for peripheral artery disease (PAD) according to established guidelines. Participants will receive a mobile health device for self-tracking only but not receive any behavioral coaching.

  • BehavioralPerformance evaluation

    Preliminary performance evaluation determine the optimal components of the Smart MOVE! intervention. Specific procedures will include: 1. Provider and stakeholder interviews 2. Peripheral artery disease (PAD) patient interviews 2\) N-of-1 trials to refine the intervention

06

What researchers measure

Primary outcomes

  1. 6-minute walk test (6MWT)

    The 6MWT is a well-validated measure of functional capacity and increasingly recognized as a meaningful outcome measure in peripheral artery disease (PAD). Participants will be asked to walk back and forth along a 100-foot hallway for six minutes using standard methods and have their total distance recorded

    Time frame: 90 days

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Oct 2026, 58 months.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's 58 months is above that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

Primary completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Nov 10, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, last on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2021
First posted
May 17, 2021
StartActual
Dec 1, 2021
Primary completionActual
Oct 26, 2026was Sep 2026
CompletionActual
Oct 26, 2026was Sep 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Oct 2, 2026 · changed Nov 10, 2026
Primary completion
Sep 30, 2026→Oct 26, 2026 (actual)
moved 2 times, Oct 2, 2026 – Nov 10, 2026
Study completion
Sep 30, 2026→Oct 26, 2026 (actual)
moved 2 times, Oct 2, 2026 – Nov 10, 2026
Enrollment
75 (estimated)→63 (actual)
Oct 2, 2026
Eligibility
1 inclusion criterion edited, 1 removed; 3 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • RemovedAge >40 years
  • EditedEstablished peripheral artery disease (PAD) diagnosis (abnormal ankle-brachial index or evidence of PAD on prior certified vascular laboratory or radiology imaging)
Exclusion criteria
  • EditedIndividuals whose walking is limited by a condition other than peripheral artery disease (PAD)
  • Editedother high-risk findings (e.g., drop of systolic blood > 20 millimetres of mercury (mmHg) with exercise)
  • EditedDeemed to be poorly suited for the study or the study intervention at the discretion of the principal investigator (PI) or study staff
Oct 2, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Edited6-minute walk test (6MWT)Time frame: 90 days
Oct 2, 2026
Documents
Oct 19, 2026
Show all 3 updates
  1. Nov 10, 2026
    Active, not recruiting→Completed
    Primary completion Oct 30, 2026→Oct 26, 2026 (now actual)
    Study completion Oct 30, 2026→Oct 26, 2026 (now actual)
    + 3 other changes: verification date, description and arm descriptions
  2. Oct 19, 2026
    Documents Informed consent form ↗ posted
  3. Oct 2, 2026
    Recruiting→Active, not recruiting
    Primary completion Sep 30, 2026→Oct 30, 2026
    Study completion Sep 30, 2026→Oct 30, 2026
    Enrollment 75 (estimated)→63 (actual)
    Eligibility 1 inclusion criterion edited, 1 removed; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • RemovedAge >40 years
    • EditedEstablished peripheral artery disease (PAD) diagnosis (abnormal ankle-brachial index or evidence of PAD on prior certified vascular laboratory or radiology imaging)
    Exclusion criteria
    • EditedIndividuals whose walking is limited by a condition other than peripheral artery disease (PAD)
    • Editedother high-risk findings (e.g., drop of systolic blood > 20 millimetres of mercury (mmHg) with exercise)
    • EditedDeemed to be poorly suited for the study or the study intervention at the discretion of the principal investigator (PI) or study staff
    Primary outcomes 1 edited
    What changed in the outcomes
    • Edited6-minute walk test (6MWT)Time frame: 90 days
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04889105
Collaborators
LifeQ
Responsible party
Sponsor
First posted
May 17, 2021
Start date
Dec 1, 2021
Primary completion
Oct 26, 2026
Completion
Oct 26, 2026
Last update
Nov 10, 2026

Study contacts

Arash Harzand, MD
principal investigator · Atlanta VA Medical and Rehab Center, Decatur, GA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion